Pol. Merkur. Lek (Pol. Med. J.), 2016, XLI/246: 287-292 Maximize

Pol. Merkur. Lek (Pol. Med. J.), 2016, XLI/246: 287-292

Title: Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block – a case report 

Authors: Osovska NY, Kuzminova NV. 

More details


40,00 zł


Ranolazine in treatment of stable angina in woman with atrial fibrillation and intermittent left bundle branch block – a case report

Osovska NY, Kuzminova NV.

Department of Internal Therapy No 1 of Vinnitsa National Pirogov Memorial Medical University, Vinnitsa, Ukraine

Stable angina is the most frequent manifestation of ischemic heart disease (IHD) in women as compared to men (65% versus 37%). IHD in women has more favorable clinical course because myocardial infarction develops twice as rare as in men. Coronary angiography of angina patients demonstrates normal coronary arteries more frequently in women than in men. Microvascular angina (MVA) is found to be a rather common form of stable IHD as that particular diagnosis is made later in 20-30% of patients who previously underwent coronary angiography. The disease occurs three times as often in women than in men irrespective of age. Most of these patients are in their perimenopausal age – 45-60 years. The major role in MVA development is considered to be decreased coronary flow reserve resulting from evident endothelial dysfunction of minor coronary arteries. MVA is characterized by great variability of its course and low response to conventional antianginal therapy, particularly in women. In view of this the problem of antianginal drugs which can be used in addition to standard therapy remains to be solved. Ranolazine is a new original antianginal medicine which improves left ventricular diastolic filling by selective inhibition of late Na-flow leading to more effective coronary vessels filling in diastole. The article presents the results of multicenter studies of ranolazine as to its effect on diastolic and systolic functions of the left ventricle, clinical manifestations of angina and heart failure as well as the data on antiarrhythmic action of ranolazine. This article describes the case of successful use of ranolazine as an additional anti-anginal medicine in the 46- year-old female patient diagnosed with microvascular angina. Before taking ranolazine, on the background of conventional treatment of coronary heart disease, the patient developed stable angina and persistent left bundle branch block, atrial fibrillation. After receiving ranolazine, 1000 mg per day for a month, Holter ECG monitoring showed not only significantly reduced number of strokes, the left bundle branch block and atrial fibrillation dissappeared as well. The results indicate a high efficiency of ranolazine as an antianginal, anti-ischemic and anti-arrythmic medicine.

Key words: microvascular angina, antianginal drugs, left ventricular diastolic dysfunction, ranolazine

Pol Med J, 2016; XLI (246); 287–29